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Abstract 
The adverse health impacts of tobacco smoking are a 
drain on national resources. This study will test an 
intervention to promote smoking cessation among young 
adults aged 18-30years. The intervention will be delivered 
within two settings in Australian health care; community 
pharmacies and general practice. The new study builds on 
the pilot data, reported here, which inform the feasibility, 
recruitment strategy, outcome measure, effect size and 
attrition rate. The new study is a randomised controlled 
trial with 200 clients recruited from general practice and 
community pharmacies in Western Australia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Background 
 
Health risks associated with smoking 
The prevalence of smoking is a major challenge in health 
care.    Tobacco  smoking  harms  almost  every  organ  in  the 
body and is a major risk factor for a large number of vascular 
and respiratory diseases and a variety of cancers, leading to 
death  or disability and drain on national resources. Most 
long-term  smokers  will  die  prematurely,  half  of  these  in 
middle  age,  as  smoking  reduces  the  life  expectancy  of  a 
heavy smoker by approximately seven years and increases 
the  remaining  life  years  in  poor  health  (1,2).    Even  light 
smokers who only consume between one to four cigarettes 
per day triple their long-term risk of dying of cardiovascular 
disease or lung cancer (3). The most recent estimate for the 
prevalence of smoking in Australia suggests that 17.4% aged 
14 years and over smoke tobacco on a daily basis, equating 
to  approximately  2.8  million  people  and  in  Western 
Australia in 2005 31.5% of school children aged 12-17 years 
had smoked at least part of a cigarette in their lifetime (4,5).  
The younger people are when they start smoking the more 
likely they are to smoke heavily and to be at increased risk 
of illness or death caused by smoking (6). 
 
Traditional quit messages 
Advertising  by  tobacco  companies  is  designed  to  have  a 
strong  emotional  impact  because  this  then  increases  the 
chances of the product being bought.  (7,8)  Individuals must 
be  encouraged  to  change  behaviour  and  this 
encouragement  needs  strong  emotional  arousal.  (9)  
Therefore, information that deepens the experience of fear 
or  guilt  seems  to  be  particularly  effective  in  initiating 
behaviour  change.  (7,10,11,12)  There  would  be  few 
Australians  now  who  could  claim  ignorance  of  the 
detrimental  health  effects  of  smoking.    However  health 
promotion  research  shows  that,  in  isolation,  knowledge 
about  the  hazards  of  smoking  is  insufficient  to  deter 
smoking  behaviours  (13).    Most  adolescents  are  naturally 
curious  about  smoking  and  experimentation  is  strongly 
predicted  where  smoking  is  prevalent  within  their  own 
environment  and  access  to  cigarettes  is  facilitated  by 
parents, siblings or friends who smoke.  Smoking initiation is 
also strongly linked to the normative and control factors of 
peer pressure, where “fitting in” with peers is an important 
social bonding experience (14). 
 
An alternative message for young smokers 
“Smoker’s Face” is the medical term used to describe the 
drastic  and  irreversible  impact  of  smoking  on  physical 
appearance.  Smoking dries out the skin and reduces blood 
circulation  leading  to  oxygen  deprivation  causing  wrinkle 
formation contributing to premature skin ageing. (15).  
 
In 1984 a West Australian advertising campaign, “Not Just a 
Pretty Face”, depicted a young, attractive woman smoking a 
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cigarette  while  gradually  morphing  into  a  relatively 
unattractive  older  person.    Two  evaluations  of  this 
campaign  concluded  that  the  advertisement  was  highly 
successful  in  deterring  girls  from  taking  up  smoking 
because  its  powerful  and  direct  message  that  smoking 
makes  you  ugly.  (16,17)    Unfortunately,  following 
generations have not been exposed to the 1984 “Not Just 
a Pretty Face” campaign and have only had exposure to 
repetitive  graphic  and  visceral  images  of  the  harmful 
effects  of  smoking,  such  as  those  used  in  the  National 
Tobacco Campaign (1997-2003) and on cigarette packets 
(2006-2007).  These images have proven to be effective in 
deterring  adolescents  from  initiating  smoking  (18) 
however,  those  that  are  already  smoking  seem  to  be 
resistant and do not heed these messages.  
 
Adolescents who have initiated smoking don’t necessarily 
consider  themselves  at  high  risk  of  developing  health 
problems  because  they  associate  such  risks  with  long-
term smokers and they intend to give up the habit sooner 
rather than later.  They believe that the long-term effects 
of  smoking  can  be  almost  entirely  avoided  by  quitting 
before they get ‘too old’ and even if they still continue to 
smoke, there’s no certainty that they will become sick as 
they all know of a relative who smoked heavily and “still 
lived to a ripe old age”.  (14)  Some of these ‘treatment 
resistant’  smokers  are  even  asthmatics  who  despite 
recommendations  to  quit  are  impervious  to  quit 
campaigns. (19)  
 
In a Norwegian study carried out among young smokers, 
59%  women  indicated  that  concerns  about  their  own 
physical  appearance  would  contribute  to  thoughts  of 
quitting (20) and in another survey, about 25% of extant 
smokers  would quit if they knew that smoking increased 
facial ageing and premature wrinkling. (21)  
 
 Many  health  care  professionals  are  nonplussed  that 
smokers  continue  to  smoke  given  the  widespread 
information that is available to them.  There is clearly a 
present  challenge  within  the  health  community  to  find 
strategies to overcome these entrenched resistances to 
the  quit  smoking  messages.  Within  this  context, 
premature ageing is a real fear to today’s youth-oriented 
society  and  emphasising  the  link  of  smoking  to  the 
detrimental effects on skin and physical appearance can 
be  an  effective  motivator  to  either  prevent  many 
adolescents from taking up smoking or to motivate them 
towards the intention to quit. (22)  
 
Expanding the role of the community pharmacist   
Community  pharmacists  are  trusted  health  care 
professionals  whose  role  is  established  in  the 
management  of  minor  illness  (23)  .    In  addition  their 
training and the availability of NRT (Nicotine Replacement 
Therapy)  make  pharmacists  well  placed  to  deliver 
smoking  cessation  interventions.  In  recent  years 
pharmacists may have diminished the emphasis on health 
care services by expanding their business into the retail 
sector  (24).    Pharmacists  need  to  differentiate  their 
businesses  by  creating  a  benefit  to  customers,  so  that 
these  customers  perceive  this  being  of  greater  value  to 
them  than  they  can  get  by  spending  money  elsewhere. 
Smoking  cessation  saves  lives,  measurably  reduces 
healthcare  costs  and  improves  well-being  and  life 
expectancies pharmacists should not only promote smoking 
cessation therapy, but take a pro-active role in advising their 
clients of the benefits of smoking cessation (25). 
 
The role of the general practitioner 
In  Australia  there  are  over  100  million  consultations  with 
general practitioners annually (26). Each consultation is an 
opportunity to promote smoking cessation. However it has 
been  shown  that  there  is  only  a  limited  increase  in  the 
motivation to quit using the tools and techniques available 
in practice (27). Only 46% of divisions of general practice 
actively  offer  smoking  cessation  advice  therefore  there  is 
considerable scope to develop more effective strategies to 
engage the patient effectively in health promotion activity 
(28).  
 
Objectives 
 
The  aim  of  this  study  is    to  test  the  efficacy  of  an 
intervention  based  on  personalised,  vivid  illustrations  of 
‘smoker’s  face’  on  quit  attempts  or  ‘state  of  change’ 
progression  attitudes  among  young  smokers  (18-30  years 
old). 
 
Methods 
 
Participants  will  be  recruited  when  they  present  at  a 
community pharmacy for any service or enrol on a smoking 
cessation clinic organised by a Division of general practice.   
Eligibility criteria:  
i)  18-30 yrs old (self-report);   
ii)  Smokers (self-report);   
iii)  Able to give consent;   
iv)   Available for follow up for 12 months (self-report);   
v)  No  beards,  moustaches  or  facial  accessories  that 
can’t be removed  
vi)  No body dysmorphia  (clients will be screened for 
BDD using the diagnostic instrument: BDDQ  - 
Body Dysmorphic Disorder Questionnaire) (29);   
They will be randomised into two groups -  a control group 
and  an  intervention  group  with  equal  number  of 
participants  in  each.  Allocation  into  control  group  and 
intervention group will alternate weekly (most feasible and 
least bias option suitable for the different settings) so that 
all  clients  recruited  in  any  specific  week  will  receive  the 
same intervention. All participants will be asked to complete 
a baseline questionnaire. 
 
The intervention: 
The  APRIL®  Age  Progression  Software  is  the  only 
statistically-based  3D  age  progression  software  now 
available. The software creates a stream of aged images of 
faces  from  a  standard  digital  photograph.  The 
wrinkling/aging algorithms are based upon research of more 
than 7,000 people of all ages, ethnicities and lifestyle habits, 
as  well  as  on  published  data  regarding  facial  changes 
associated  with  aging.  Additionally,  the  resulting  aged  Australasian Medical Journal 2009, 1, 7, 8-12 
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images can be adjusted to compare how a person will age 
as  a  smoker  verses  a  nonsmoker;  if  he  or  she  adds 
excessive weight; or if they experience a high degree of 
unprotected  sun  exposure.  See  demonstration  video 
accompanying this report. 
 
Control Group 
Participants  will  receive  standard  smoking  cessation 
advice by a pharmacist or smoking cessation clinic officer. 
In pharmacy this comprises the Pharmacy Self Care card 
on Smoking (a health information card from the Pharmacy 
Self  Care  program  of  the  Pharmaceutical  Society  of 
Australia) and counselling. In general practice this will be 
the 5A’s approach to smoking cessation (30).  They will be 
asked to complete the Baseline questionnaire consisting 
of  demographic  data  and  the  Fagerstrom  scale.  This 
procedure from pre-screening to completion of Baseline 
questionnaire is estimated to take 5 minutes.  Follow-up 
surveys will be undertaken via telephone at 1 month, 3 
months, 6 months and 12 months later and will take 5 
minutes each to complete. 
 
Intervention Group 
Participants  will  receive  the  same  smoking  cessation 
advice as the control group from the pharmacist General 
practitioners or smoking cessation clinic team.  They will 
also  be  asked  to  complete  the  Baseline  questionnaire.  
Then they will be photographed and their images digitally 
aged,  as  a  smoker  and  non-smoker,  using  APRIL  age 
software and invited to view the age-processed images.  
This procedure from pre-screening to completion of post-
intervention  questionnaire  will  take  10  minutes.    If 
participants become distressed or should they express an 
interest in smoking cessation, they will be counselled by 
the relevant health practitioner. A photo (ie. a coloured 
printed  photocopy)  of  their  photo-aged  face  will  be 
posted to them, to their nominated address within a week 
of the intervention.  Follow-up surveys will be undertaken 
via telephone at 1 month, 3 months, 6 months, and 12 
months later and will take 5 minutes each to complete. 
 
The ‘Smoker’s Face’ Personal Threat-Appeal Simulations 
The  ‘smoker’s  face’  threat  appeal  simulations  will  be 
created using a digital photograph taken of participants 
and  inputted  to  APRIL®  Age  Progression  Software  on  a 
laptop computer.  
The creation of the simulations involves: 
a)  delineating  a  ‘target’  (smoker’s  and  non-
smoker’s) face according to a predefined set of 
feature points; 
b)  distorting  the  delineations  into  a  new 
configuration  (based  on  health  data  from  the 
faces  of  smokers  and  non-smokers,  taking  into 
account of gender and race); 
c)  remapping textures (ie. pixel intensities) into the 
newly generated simulation.   
The result is a colour, lifelike simulation of a person’s face 
if  he  or  she  were  to  continue  or  become  a  smoker 
compared to a non-smoker’s normally aged face. 
The  simulations  will  be  presented  on  a  laptop  computer 
with  a  15.2  inch  monitor  with  a  screen  resolution  of 
1152x760  (85Hz), set to millions of colours.   
 
Outcomes measure 
 
The effect of the intervention will be measured using quit 
attempts and the Fagerstrom Scale as a measure of  nicotine 
dependence (31). 
 
Sample size 
Sample sizes have been calculated on the basis of a pilot 
study with 50 subjects, 25 in the intervention group and 25 
in the control group .There were 17 (34%) male subjects, 
and 33 (66%) Female.  Of the control group, 11/25 (44%) 
were male, while only 6/25 (24%) of the intervention group 
were  male.    The  responses  to  6  questions  were  used  to 
calculate the Fagerstrom score – a number between zero 
and  10  indicating  the  level  of  dependence  on  smoking. 
Higher  scores  indicate  greater  nicotine  dependence. 
Previous studies using this scale have divided subjects into 5 
groups (scores: 0-2, 3-4, 5, 6-7, 8-10).  Those subjects who 
had  stopped  smoking  at  the  time  of  questionnaire  were 
allocated a Fagerstrom score of -1 in order to distinguish 
them  from  very  low-dependence  smokers.    We  assumed 
that those participants who did not complete a follow up 
survey in our pilot study had the same smoking dependence 
as  their  previous  survey.    Six  subjects  were  classified  as 
‘Quitters’ at 3 months, and they all came from the lowest 
smoking dependence category (0-2) at baseline.  For these 
subjects,  there  was  no  significant  difference  between 
treatment  allocation  groups  (p=0.29).  For  subjects  who 
started out with a greater smoking dependence (Fagerstrom 
score 3+), there was a trend towards a greater proportion of 
the Intervention group moving to a lower dependence by 3 
months  (p=0.11).  From  the  effect  size  seen  in  the  ‘mean 
smoking dependency scores’ of the control and intervention 
groups, a sample size of 200 was calculated which would be 
required for a definitive RCT in each setting with 80% power 
and 5% significance.  This would allow for a 50% attrition 
rate. 
 
Data analysis 
The quantitative research data will be analysed using SPSS 
Statistics  v17  software.  The  profile  of  the  subjects  under 
study will be summarised using descriptive statistics (means 
and  Standard  deviations  for  continuous  variables,  and 
proportions  for  categorical  variables).    Univariate  group 
comparisons  will  be  performed  using  Chi-square  tests 
(categorical  variables),  and  t-tests  (continuous  variables).  
Multivariate  analyses  of  continuous  variables  will  be 
performed using Analysis of Variance (possibly a repeated 
measures analysis for endpoints measured at several time 
points through the study).  Multivariate Logistic regression 
may be used to analyse the binary endpoint variables (for 
example:    very  low  dependence  vs  other),  in  order  to 
compare  treatment  groups  after  adjustment  for  other 
factors.    If  the  continuous  variables  exhibit  excessive 
skewness,  non-parametric  methods  may  be  used  in 
preference to the Analysis of Variance. 
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